Back to Trials
NCT05960929PHASE3Recruiting

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS

ONY

Start Date

1/1/2025

Completion Date

4/1/2026

Summary

The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.

Detailed Description

This single-dose, double-blind, random allocation, sham-control, clinical trial will recruit spontaneously breathing newborns with RDS stable on non-invasive nasal respiratory support. Enrolled clinical study subjects will be randomly allocated to receive respiratory air with Infasurf® (Intervention Arm) or respiratory air alone (Sham Control Arm) through the InfasurfAero™. The objectives of this clinical study are to i) assess the effectiveness of a single dose of Infasurf administered through the InfasurfAero in preventing CPAP failure, and ii) assess the safety of Infasurf administered through the InfasurfAero. Subjects will be enrolled at one of 10+ sites. 7 sites are currently recruited.

Eligibility Criteria

Age Range: No minimum to No maximum

Inclusion Criteria: Inclusion criteria include ALL of the following: 1. Written informed consent obtained by parent or legal representative prior to or after birth 2. Gestational age at birth ≥ 29 0/7 AND ≤ 35 6/7 weeks 3. Birthweight ≥ 1,000 AND ≤ 3,500 grams 4. Age ≥ 1 hour AND ≤ 6 hours 5. Clinical diagnosis of surfactant-deficient RDS, with EITHER i. a Silverman-Anderson Retraction Score ≥ 5 (in Room Air), OR ii. signs of respiratory distress (tachypnea, retractions, grunting) AND radiographic confirmation 6. Require CPAP 7. Respiratory Severity Score (RSS) ≥ 1.25 AND ≤ 2.4 8. If subject is \>346/7 weeks' gestation a chest radiograph is required Exclusion Criteria: Exclusion criteria are ANY of the following: 1. Surfactant administration prior to randomization 2. Mechanical ventilation prior to randomization 3. Major congenital anomaly (suspected or confirmed) 4. Abnormality of the airway (suspected or confirmed) 5. Respiratory distress presumed secondary to an etiology other than RDS (e.g., suspected pulmonary hypoplasia, pneumothorax, meconium aspiration syndrome, pneumonia, septic or hypovolemia shock, hypoxic ischemic encephalopathy) 6. Apgar score \< 3 at 5 minutes of age 7. Umbilical cord gas pH \<7.0 or BD \> 10 8. Any condition that, in the opinion of the Investigator, would place the neonate at undue risk

Interventions

COMBINATION_PRODUCT

Infasurf Aero™

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Respiratory Distress Syndrome (Neonatal)Intubation ComplicationDeath; Neonatal

Locations

St. Josephs Hospital and Medical Center

Phoenix, Arizona 85013

United States

Phoenix Children's

Phoenix, Arizona 85016

United States

Sharp Mary Birch Hospital for Women & Newborns

San Diego, California 92123

United States

University of Florida -Jacksonville

Jacksonville, Florida 32209

United States

Kapi'olani Medical Center for Women & Children

Honolulu, Hawaii 96826

United States

Jersey Shore University Medical Center

Neptune City, New Jersey 07753

United States

Sisters of Charity Hospital

Buffalo, New York 14214

United States

Western TN- Jackson-Madison County General Hospital

Jackson, Tennessee 38301

United States

Utah Valley Hospital

Provo, Utah 84604

United States

Unity Point Meriter

Madison, Wisconsin 53715

United States